Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Zymeworks downgraded to Market Perform at SVB Leerink » 09:23
02/25/21
02/25
09:23
02/25/21
09:23
ZYME

Zymeworks

$40.25 /

-0.77 (-1.88%)

As previously reported,…

As previously reported, SVB Leerink analyst Andrew Berens downgraded Zymeworks to Market Perform from Outperform with a price target of $41, down from $50. The analyst thinks is likely to be a continued overhang from lack of clarity around the key asset, ZW49. Berens says he hosted a fireside chat with CEO Ali Tehrani and it was unclear to him when the next update for ZW49 would occur given that the company has decided to wait to present the dose escalation part of the trial until they have confirmed efficacy from about 10 patients in a single tumor type from the recently initiated dose expansion cohorts.

ShowHide Related Items >><<
ZYME Zymeworks
$40.25 /

-0.77 (-1.88%)

ZYME Zymeworks
$40.25 /

-0.77 (-1.88%)

02/25/21 SVB Leerink
Zymeworks downgraded to Market Perform from Outperform at SVB Leerink
02/08/21 H.C. Wainwright
Zymeworks assumed with a Buy at H.C. Wainwright
01/29/21 Citi
Zymeworks upgraded to Buy from Neutral at Citi (yesterday)
01/28/21 SVB Leerink
Zymeworks price target lowered to $50 from $66 at SVB Leerink
ZYME Zymeworks
$40.25 /

-0.77 (-1.88%)

Downgrade
Zymeworks downgraded to Market Perform from Outperform at SVB Leerink » 06:50
02/25/21
02/25
06:50
02/25/21
06:50
ZYME

Zymeworks

$40.25 /

-0.77 (-1.88%)

SVB Leerink analyst…

SVB Leerink analyst Andrew Berens downgraded Zymeworks to Market Perform from Outperform with a $41 price target.

ShowHide Related Items >><<
ZYME Zymeworks
$40.25 /

-0.77 (-1.88%)

ZYME Zymeworks
$40.25 /

-0.77 (-1.88%)

02/08/21 H.C. Wainwright
Zymeworks assumed with a Buy at H.C. Wainwright
01/29/21 Citi
Zymeworks upgraded to Buy from Neutral at Citi (yesterday)
01/28/21 SVB Leerink
Zymeworks price target lowered to $50 from $66 at SVB Leerink
01/28/21 Wells Fargo
Zymeworks price target lowered to $56 from $71 at Wells Fargo
ZYME Zymeworks
$40.25 /

-0.77 (-1.88%)

Earnings
Zymeworks reports Q4 EPS (74c), consensus ($1.22) » 16:29
02/24/21
02/24
16:29
02/24/21
16:29
ZYME

Zymeworks

$40.25 /

-0.77 (-1.88%)

Reports Q4 revenue…

Reports Q4 revenue $15.68M, consensus $10.3M. The company said, "Throughout 2020, we initiated and advanced several clinical trials and achieved important regulatory milestones for zanidatamab and ZW49. This has set up 2021 to be a data-rich year for both of our lead clinical assets as well as new preclinical candidates and therapeutic platforms, and we are well resourced to deliver on our priorities." As of December 31, 2020, Zymeworks had $451.6M in cash resources consisting of cash, cash equivalents, short-term investments and certain long-term investments. It added,

ShowHide Related Items >><<
ZYME Zymeworks
$40.25 /

-0.77 (-1.88%)

ZYME Zymeworks
$40.25 /

-0.77 (-1.88%)

02/08/21 H.C. Wainwright
Zymeworks assumed with a Buy at H.C. Wainwright
01/29/21 Citi
Zymeworks upgraded to Buy from Neutral at Citi (yesterday)
01/28/21 SVB Leerink
Zymeworks price target lowered to $50 from $66 at SVB Leerink
01/28/21 Wells Fargo
Zymeworks price target lowered to $56 from $71 at Wells Fargo
ZYME Zymeworks
$40.25 /

-0.77 (-1.88%)

Initiation
Zymeworks assumed with a Buy at H.C. Wainwright » 06:08
02/08/21
02/08
06:08
02/08/21
06:08
ZYME

Zymeworks

/

+

H.C. Wainwright analyst…

H.C. Wainwright analyst Robert Burns assumed coverage of Zymeworks with a Buy rating and $57 price target. 2021 is likely to be a "catalyst-rich" period for the company, which is slated to report data from several clinical-stage programs in the coming months, Burns tells investors in a research note.

ShowHide Related Items >><<
ZYME Zymeworks
/

+

ZYME Zymeworks
/

+

01/29/21 Citi
Zymeworks upgraded to Buy from Neutral at Citi (yesterday)
01/28/21 SVB Leerink
Zymeworks price target lowered to $50 from $66 at SVB Leerink
01/28/21 Wells Fargo
Zymeworks price target lowered to $56 from $71 at Wells Fargo
01/28/21 Barclays
Zymeworks price target lowered to $38 from $47 at Barclays
ZYME Zymeworks
/

+

Over a month ago
Upgrade
Zymeworks upgraded to Buy from Neutral at Citi (yesterday) » 06:36
01/29/21
01/29
06:36
01/29/21
06:36
ZYME

Zymeworks

$34.46 /

-9.66 (-21.89%)

Citi analyst Yigal…

Citi analyst Yigal Nochomovitz yesterday morning upgraded Zymeworks to Buy from Neutral with an unchanged price target of $53. The analyst sees a better risk/reward following the recent selloff. The probability of success for ZW49 should not be lowered from the current 60% assumption because safety looks "very favorable" at the go-forward expansion dose and there is not enough information to properly evaluate efficacy, Nochomovitz told investors in a research note.

ShowHide Related Items >><<
ZYME Zymeworks
$34.46 /

-9.66 (-21.89%)

ZYME Zymeworks
$34.46 /

-9.66 (-21.89%)

01/28/21 SVB Leerink
Zymeworks price target lowered to $50 from $66 at SVB Leerink
01/28/21 Wells Fargo
Zymeworks price target lowered to $56 from $71 at Wells Fargo
01/28/21 Barclays
Zymeworks price target lowered to $38 from $47 at Barclays
01/25/21 Citi
Zymeworks downgraded to Neutral ahead of initial ZW49 data at Citi
ZYME Zymeworks
$34.46 /

-9.66 (-21.89%)

Hot Stocks
Zymeworks falls -22.8% » 10:00
01/28/21
01/28
10:00
01/28/21
10:00
ZYME

Zymeworks

$33.90 /

-10.22 (-23.16%)

Zymeworks is down -22.8%,…

Zymeworks is down -22.8%, or -$10.04 to $34.02.

ShowHide Related Items >><<
ZYME Zymeworks
$33.90 /

-10.22 (-23.16%)

ZYME Zymeworks
$33.90 /

-10.22 (-23.16%)

01/28/21 SVB Leerink
Zymeworks price target lowered to $50 from $66 at SVB Leerink
01/28/21 Wells Fargo
Zymeworks price target lowered to $56 from $71 at Wells Fargo
01/28/21 Barclays
Zymeworks price target lowered to $38 from $47 at Barclays
01/25/21 Citi
Zymeworks downgraded to Neutral ahead of initial ZW49 data at Citi
ZYME Zymeworks
$33.90 /

-10.22 (-23.16%)

Recommendations
Zymeworks price target lowered to $50 from $66 at SVB Leerink » 09:21
01/28/21
01/28
09:21
01/28/21
09:21
ZYME

Zymeworks

$44.12 /

-2.18 (-4.71%)

SVB Leerink analyst…

SVB Leerink analyst Andrew Berens lowered the firm's price target on Zymeworks to $50 from $66 and keeps an Outperform rating on the shares. The analyst notes that Zymeworks has announced initial ZW49 clinical data from the Phase 1 dose escalation study. Despite tempered investor expectations for the quantity of data to be seen at this update, he thinks the level of efficacy fell short of expectations. While Berens previously believed this event could de-risk ZW49, he now thinks the update may have created more questions than answers, pending a more detailed readout at an upcoming medical conference in the back half of the year.

ShowHide Related Items >><<
ZYME Zymeworks
$44.12 /

-2.18 (-4.71%)

ZYME Zymeworks
$44.12 /

-2.18 (-4.71%)

01/28/21 Wells Fargo
Zymeworks price target lowered to $56 from $71 at Wells Fargo
01/28/21 Barclays
Zymeworks price target lowered to $38 from $47 at Barclays
01/25/21 Citi
Zymeworks downgraded to Neutral ahead of initial ZW49 data at Citi
01/25/21 Citi
Zymeworks downgraded to Neutral from Buy at Citi
ZYME Zymeworks
$44.12 /

-2.18 (-4.71%)

Recommendations
Zymeworks price target lowered to $56 from $71 at Wells Fargo » 07:50
01/28/21
01/28
07:50
01/28/21
07:50
ZYME

Zymeworks

$44.12 /

-2.18 (-4.71%)

Wells Fargo analyst Jim…

Wells Fargo analyst Jim Birchenough lowered the firm's price target on Zymeworks to $56 from $71 and keeps an Overweight rating on the shares following interim data from the company's phase 1 dose escalation of novel HER2 ADC therapeutic ZW49. While it is still difficult to benchmark ZW49 to category leader ENHERTU, with continued dose escalation and a mixture of HER2 tumor types, the analyst believes the drug is active in a heavily pre-treated HER2 basket with safety profile allowing for additional optimization. Birchenough views base support for Zymeworks on lead HER2 antibody zanidatamab at $38 and sees significant option value to continued dose optimization of ZW49 and cohort expansion in key tumor types where more appropriate comparison to ENHERTU can be made.

ShowHide Related Items >><<
ZYME Zymeworks
$44.12 /

-2.18 (-4.71%)

ZYME Zymeworks
$44.12 /

-2.18 (-4.71%)

01/28/21 Barclays
Zymeworks price target lowered to $38 from $47 at Barclays
01/25/21 Citi
Zymeworks downgraded to Neutral ahead of initial ZW49 data at Citi
01/25/21 Citi
Zymeworks downgraded to Neutral from Buy at Citi
01/12/21 SVB Leerink
Zymeworks price target raised to $66 from $45 at SVB Leerink
ZYME Zymeworks
$44.12 /

-2.18 (-4.71%)

Recommendations
Zymeworks price target lowered to $38 from $47 at Barclays » 06:43
01/28/21
01/28
06:43
01/28/21
06:43
ZYME

Zymeworks

$44.12 /

-2.18 (-4.71%)

Barclays analyst Gena…

Barclays analyst Gena Wang lowered the firm's price target on Zymeworks to $38 from $47 and keeps an Equal Weight rating on the shares. The analyst views the company's interim data of the Phase 1 dose-escalation trial of ZW49 in HER2-positive cancers as "underwhelming."

ShowHide Related Items >><<
ZYME Zymeworks
$44.12 /

-2.18 (-4.71%)

ZYME Zymeworks
$44.12 /

-2.18 (-4.71%)

01/25/21 Citi
Zymeworks downgraded to Neutral ahead of initial ZW49 data at Citi
01/25/21 Citi
Zymeworks downgraded to Neutral from Buy at Citi
01/12/21 SVB Leerink
Zymeworks price target raised to $66 from $45 at SVB Leerink
01/12/21 Wells Fargo
Zymeworks price target raised to $71 from $58 at Wells Fargo
ZYME Zymeworks
$44.12 /

-2.18 (-4.71%)

Hot Stocks
Zymeworks begins patient enrollment into expansion cohort of ph1 ZW49 trial » 17:17
01/27/21
01/27
17:17
01/27/21
17:17
ZYME

Zymeworks

$44.12 /

-2.18 (-4.71%)

The company states:…

The company states: "Zymeworks announced that the company has begun enrolling patients into the expansion cohort portion of the ongoing Phase 1 clinical trial for ZW49, its novel HER2-targeted antibody-drug conjugate. Supporting data from the Phase 1 dose escalation portion were highlighted today via a webcast and conference call and are summarized below. The dose escalation portion of the study employed a standard 3 + 3 design to evaluate escalating doses within different dosing regimens including once every two week (Q2W) and once every three week (Q3W) schedules with the objective of selecting a dose and schedule to advance into the expansion cohorts. To date patients from sites across the US and Canada with a variety of heavily pretreated HER2-positive cancer types have been enrolled, including breast cancer, gastroesophageal adenocarcinoma, gynecologic cancers, non-small cell lung cancer, anal cancer, and colorectal cancer. In the 35 patients who have received ZW49 across all dosing regimens, there have been no dose limiting toxicities, no treatment-related hematologic toxicities including neutropenia or thrombocytopenia, no treatment-related pulmonary toxicity including interstitial lung disease or pneumonitis, and no treatment-related liver toxicity. There have been no treatment-related deaths." Over 90% of treatment-related adverse events have been mild or moderate (Grade 1 or 2) in severity, with the most common being keratitis, fatigue, and diarrhea, which have been reversible and manageable in an outpatient setting. There have been no discontinuations due to treatment-related adverse events, and the maximum-tolerated dose has not yet been established.

ShowHide Related Items >><<
ZYME Zymeworks
$44.12 /

-2.18 (-4.71%)

ZYME Zymeworks
$44.12 /

-2.18 (-4.71%)

01/25/21 Citi
Zymeworks downgraded to Neutral ahead of initial ZW49 data at Citi
01/25/21 Citi
Zymeworks downgraded to Neutral from Buy at Citi
01/12/21 SVB Leerink
Zymeworks price target raised to $66 from $45 at SVB Leerink
01/12/21 Wells Fargo
Zymeworks price target raised to $71 from $58 at Wells Fargo
ZYME Zymeworks
$44.12 /

-2.18 (-4.71%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.